Articles from eGenesis

eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation, today announced the appointments of Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer.

eGenesis, a biotechnology company developing human-compatible organs for transplantation, today announced that Michael Curtis, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2026 titled "Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage."

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced that Mike Curtis, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:30 p.m. PT.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a clinical trial evaluating EGEN-2784, a genetically engineered porcine-derived kidney, in patients with end stage kidney disease (ESKD).

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Jay Barth, M.D., to the company's executive management team as Chief Medical Officer (CMO). Dr. Barth joins eGenesis with over 25 years of industry experience in clinical development and medical affairs, most recently having served as CMO of Ascidian Therapeutics.

eGenesis, a biotechnology company developing human-compatible engineered organs to treat patients suffering from organ failure, and OrganOx Ltd., a leading organ medical technology company, today announced the U.S. Food & Drug Administration (FDA) has cleared the investigational new drug (IND) application for EGEN-5784, a human-compatible, genetically engineered porcine liver, used in combination with the OrganOx extracorporeal liver cross-circulation (ELC) system, for patients with acute-on-chronic liver failure (ACLF) suffering from decompensated liver function in the intensive care setting.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the successful transplantation of a genetically engineered porcine kidney into a second patient living with end-stage kidney disease.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and OrganOx, a medical device company with a focus on the therapeutic applications of isolated organ perfusion, today announced the successful completion of an extracorporeal perfusion of a brain-dead research donor using a genetically engineered porcine liver. The donor was the first to be enrolled in the ongoing PERFUSE-2 study.

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, will present new data and host a symposium during the IPITA (International Pancreas and Islet Transplant Association), IXA (International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society) joint congress, held in San Diego, October 26-29, 2023.

- Proof of concept study resulted in life-supporting organ function and recipient survival of over two years   

Data support physiological viability of porcine kidney transplantation, highlight areas for future clinical monitoring and potential pharmaceutical intervention

Additional presentations highlight new findings on xenotransplantation graft rejection, providing potential methods to predict and improve future clinical outcomes

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer. Dr. Niss is a seasoned biotechnology executive with more than 20 years of experience spearheading the development and manufacturing of novel therapies across cell and gene therapy, regenerative medicine, and oncology.

-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients-